IMV Inc. (IMV): Price and Financial Metrics


IMV Inc. (IMV): $2.16

0.02 (+0.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMV Stock Summary

  • IMV's price/sales ratio is 114.24; that's higher than the P/S ratio of 97.68% of US stocks.
  • The volatility of IMV INC's share price is greater than that of 98.09% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for IMV comes in at -122.38% -- higher than that of merely 4.69% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to IMV INC, a group of peers worth examining would be SABS, BGRY, NBTX, IKT, and TMBR.
  • Visit IMV's SEC page to see the company's official filings. To visit the company's web site, go to imv-inc.com.

IMV Price Target

For more insight on analysts targets of IMV, see our IMV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.75 Average Broker Recommendation 1.75 (Moderate Buy)

IMV Stock Price Chart Interactive Chart >

Price chart for IMV

IMV Price/Volume Stats

Current price $2.16 52-week high $15.30
Prev. close $2.14 52-week low $2.02
Day low $2.04 Volume 90,402
Day high $2.20 Avg. volume 180,206
50-day MA $2.68 Dividend yield N/A
200-day MA $5.91 Market Cap 20.65M

IMV Inc. (IMV) Company Bio


IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma). DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials. The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.


IMV Latest News Stream


Event/Time News Detail
Loading, please wait...

IMV Latest Social Stream


Loading social stream, please wait...

View Full IMV Social Stream

Latest IMV News From Around the Web

Below are the latest news stories about IMV INC that investors may wish to consider to help them evaluate IMV as an investment opportunity.

IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass., January 08, 2023--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S).

Yahoo | January 8, 2023

IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 20, 2022--IMV Inc. ("IMV" or the "Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today the closing of its previously announced registered direct offering (the "Offering") for the sale of an aggregate of 3,448,276 common shares (or common share equivalents) (each,

Yahoo | December 20, 2022

IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 16, 2022--IMV Inc. ("IMV" or the "Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today that it has entered into definitive agreements for the sale of an aggregate of 3,448,276 common shares (or common share equivalents) (each, a "Share" and, collectively, the "Sha

Yahoo | December 16, 2022

IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass., December 15, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Ce

Yahoo | December 15, 2022

IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 13, 2022--IMV Inc. (the "Corporation" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that its common shares commence trading post consolidation today.

Yahoo | December 13, 2022

Read More 'IMV' Stories Here

IMV Price Returns

1-mo -12.41%
3-mo -42.40%
6-mo -57.73%
1-year -80.00%
3-year -95.12%
5-year -95.83%
YTD -11.11%
2022 -80.08%
2021 -60.39%
2020 6.21%
2019 -43.91%
2018 -13.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7613 seconds.